Comparison of asthma phenotypes in OVA-induced mice challenged via inhaled and intranasal routes

• Published in: BMC pulmonary medicine Vol. 19; no. 1; pp. 241 - 11
• Main Authors: Kim, Dong Im, Song, Mi-Kyung, Lee, Kyuhong
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 10.12.2019; BioMed Central; BMC
• Subjects: Albumin; Allergens; Allergic asthma; Allergies; Aluminum hydroxide; Alveoli; Animal model; Animal models; Asthma; Asthma phenotypes; Bronchus; Challenge routes; Comparative analysis; Cytokines; Enzyme-linked immunosorbent assay; Enzymes; Epithelial cells; Genetic aspects; Genotype & phenotype; Homeopathy; Immunoglobulin E; Inflammation; Inhalation; Interleukins; Intranasal administration; Lung diseases; Lungs; Lymphocytes T; Materia medica and therapeutics; Ovalbumin; Ovalbumin sensitization; Phenotype; Phenotypes; Pulmonology; Respiratory system; Respiratory tract; Respiratory tract diseases; Scientific equipment and supplies industry; Therapeutics; Western blotting; United States; United States > US; Allergic asthma; Animal model; Challenge routes; Ovalbumin sensitization; Asthma phenotypes
• ISSN: 1471-2466; 1471-2466
• DOI: 10.1186/s12890-019-1001-9

The respiratory system is exposed to various allergens via inhaled and intranasal routes. Murine models of allergic lung disease have been developed to clarify the mechanisms underlying inflammatory responses and evaluate the efficacy of novel therapeutics. However, there have been no comparative studies on differences in allergic phenotypes following inhaled vs. intranasal allergen challenge. In this study, we compared the asthmatic features of mice challenged via different routes following allergen sensitization and investigated the underlying mechanisms. To establish ovalbumin (OVA)-induced allergic asthma models, BALB/c mice were sensitized to 20 μg OVA with 1 mg aluminum hydroxide by the intraperitoneal route and then challenged by inhalation or intranasal administration with 5% OVA for 3 consecutive days. Cellular changes and immunoglobulin (Ig) E levels in bronchoalveolar lavage fluid (BALF) and serum, respectively, were assessed. Histological changes in the lungs were examined by hematoxylin and eosin (H&E) and periodic acid Schiff (PAS) staining. Levels of T helper (Th)2 cytokines including interleukin (IL)-4, -5, and -13 in BALF and epithelial cytokines including IL-25 and -33 in BALF and lung tissues were measured by enzyme-linked immunosorbent assay and western blotting. Airway hyperresponsiveness (AHR) was evaluated by assessing airway resistance (Rrs) and elastance (E) via an invasive method. OVA-sensitized and challenged mice showed typical asthma features such as airway inflammation, elevated IgE level, and AHR regardless of the challenge route. However, H&E staining showed that inflammation of pulmonary vessels, alveolar ducts, and alveoli were enhanced by inhaled as compared to intranasal OVA challenge. PAS staining showed that intranasal OVA challenge induced severe mucus production accompanied by inflammation in bronchial regions. In addition, Th2 cytokine levels in BALF and AHR in lung were increased to a greater extent by inhalation than by intranasal administration of OVA. Epithelial cytokine expression, especially IL-25, was increased in the lungs of mice in the inhaled OVA challenge group. OVA-sensitized mice exhibit different pathophysiological patterns of asthma including expression of epithelial cell-derived cytokines depending on the OVA challenge route. Thus, some heterogeneous phenotypes of human asthma can be replicated by varying the mode of delivery after OVA sensitization.